Canopy Growth Corporation (NASDAQ: CGC), a leading global cannabis company, has expanded its medical cannabis offerings in Australia by introducing its Canadian-grown 7ACRES brand, featuring two high-THC sativa strains: Ultra Jack and Jack Frost.
Ultra Jack, a cross between Ultra Sour and Jack Haze, is one of 7ACRES’ top-performing strains in Canada’s medical and adult-use markets. Jack Frost, derived from White Widow and Cold Creek Kush genetics, further diversifies the company’s strain lineup. Both products are initially available in 10-gram flower formats, aimed at meeting the needs of patients seeking high-quality medical cannabis options.
Andrew Bevan, Senior Vice President of Global Medical at Canopy Growth, stated, “Introducing 7ACRES to Australia broadens access to premium, high-quality flower strains for patients and prescribers. Our strengthened global supply chain ensures consistent quality and reliable delivery to meet growing demand.”
CEO Luc Mongeau highlighted international medical cannabis as a key commercial focus for Canopy Growth, emphasizing the company’s ability to scale production in Canada and supply international markets reliably.
The addition of 7ACRES builds on Canopy Growth’s existing portfolio in Australia, which currently includes Tweed flower products and Spectrum Therapeutics cannabis oils available in multiple formulations. This expansion reinforces the company’s long-term strategy to develop a scalable global medical cannabis platform.
The post Canopy Growth Strengthens Global Medical Cannabis Portfolio with New 7ACRES Strains Launch in Australia appeared first on PRISM MarketView.
